530 related articles for article (PubMed ID: 18364004)
1. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase in immune suppression and cancer.
Muller AJ; Prendergast GC
Curr Cancer Drug Targets; 2007 Feb; 7(1):31-40. PubMed ID: 17305476
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
Muller AJ; Malachowski WP; Prendergast GC
Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
6. Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction?
Löb S; Königsrainer A
Langenbecks Arch Surg; 2008 Nov; 393(6):995-1003. PubMed ID: 18064486
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.
Prendergast GC; Smith C; Thomas S; Mandik-Nayak L; Laury-Kleintop L; Metz R; Muller AJ
Cancer Immunol Immunother; 2014 Jul; 63(7):721-35. PubMed ID: 24711084
[TBL] [Abstract][Full Text] [Related]
8. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Brochez L; Chevolet I; Kruse V
Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
10. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
Johnson TS; Munn DH
Immunol Invest; 2012; 41(6-7):765-97. PubMed ID: 23017145
[TBL] [Abstract][Full Text] [Related]
11. Marrying immunotherapy with chemotherapy: why say IDO?
Muller AJ; Prendergast GC
Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
[TBL] [Abstract][Full Text] [Related]
12. The immunoregulatory role of IDO-producing human dendritic cells revisited.
Terness P; Chuang JJ; Opelz G
Trends Immunol; 2006 Feb; 27(2):68-73. PubMed ID: 16406698
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
14. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
16. IDO-expressing regulatory dendritic cells in cancer and chronic infection.
Popov A; Schultze JL
J Mol Med (Berl); 2008 Feb; 86(2):145-60. PubMed ID: 17876564
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
18. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.
von Bergwelt-Baildon MS; Popov A; Saric T; Chemnitz J; Classen S; Stoffel MS; Fiore F; Roth U; Beyer M; Debey S; Wickenhauser C; Hanisch FG; Schultze JL
Blood; 2006 Jul; 108(1):228-37. PubMed ID: 16522817
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine-2,3-dioxygenase modulation of allergic immune responses.
Le AV; Broide DH
Curr Allergy Asthma Rep; 2006 Feb; 6(1):27-31. PubMed ID: 16476191
[TBL] [Abstract][Full Text] [Related]
20. Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V
Future Oncol; 2020 Dec; 16(36):3085-3094. PubMed ID: 32976029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
